Merck shuffles the Kelun deck again
Claudin18.2 is out, but the US big pharma opts in to a new project.
CD19 is worth $700m to Merck
Merck turns to China for a molecule against one of biopharma’s most extensively studied antigens.
TIGIT blows up in a trial that always looked risky
Keyvibe-008 is halted for futility, an outcome that might have been foreseen in 2022.
FDA sends a warning about perioperative cancer studies
An adcom on Imfinzi’s Aegean trial will show whether neoadjuvant and adjuvant benefits must be split out.
Novartis drops out of KRAS
While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.
Immutep tries again
After Tacti-003’s controlled cohorts fail, Immutep plays up single-arm data in PD-L1 non-expressers.
Scancell faces its big decision
Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.
